Cardio-psycho-metabolic outcomes of bariatric surgery: design and baseline of the WAS trial
Obesity is a rapidly emerging health problem and an established risk factor for cardiovascular diseases. Bariatric surgery profoundly reduces body weight and mitigates sequelae of obesity. The open, randomized controlled Würzburg Adipositas Studie (WAS) trial compares the effects of Roux-en-Y gastri...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ann-Cathrin Koschker [verfasserIn] Bodo Warrings [verfasserIn] Caroline Morbach [verfasserIn] Florian Seyfried [verfasserIn] Nicole Rickert [verfasserIn] Pius Jung [verfasserIn] Andreas Geier [verfasserIn] Ulrich Dischinger [verfasserIn] Maike Krauthausen [verfasserIn] Martin J Herrmann [verfasserIn] Christine Stier [verfasserIn] Stefan Frantz [verfasserIn] Uwe Malzahn [verfasserIn] Stefan Störk [verfasserIn] Martin Fassnacht [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Endocrine Connections - Bioscientifica, 2013, 11(2022), 2, Seite 17 |
|---|---|
| Übergeordnetes Werk: |
volume:11 ; year:2022 ; number:2 ; pages:17 |
| Links: |
|---|
| Katalog-ID: |
DOAJ04593939X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ04593939X | ||
| 003 | DE-627 | ||
| 005 | 20230308101102.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)DOAJ04593939X | ||
| 035 | |a (DE-599)DOAJd699864de0534787aebd19b3f696e017 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC648-665 | |
| 100 | 0 | |a Ann-Cathrin Koschker |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardio-psycho-metabolic outcomes of bariatric surgery: design and baseline of the WAS trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Obesity is a rapidly emerging health problem and an established risk factor for cardiovascular diseases. Bariatric surgery profoundly reduces body weight and mitigates sequelae of obesity. The open, randomized controlled Würzburg Adipositas Studie (WAS) trial compares the effects of Roux-en-Y gastric bypass (RYGB) vs psychotherapy-supported lifestyle modification in morbidly obese patients. The co-primar y endpoint addresses 1-year changes in cardiovascular function (peak VO2 during cardiopulmonary exercise testing) and the quality of life (QoL) (Short-Form-36 physical functioning scale). Prior to randomization, all included patients underwent a multimodal ant i-obesity treatment for 6–12 months. Thereafter, the patients were randomized and followed through month 12 to collect the primary endpoints. Afterwards, patients in the lifestyle group could opt for surgery, and final visit was scheduled for all patients 24 m onths after randomization. Sample size calculation suggested to enroll 90 patients in order to arrive at minimally 22 patients per group evaluable for the primary endpoint. Secondary objectives were to quantify changes in body weight, left ventricular hypertrophy, systolic and diastolic function (by echocardiography and cardiac MRI), functional brain MRI, psychometric scales, and endothelial and metabolic function. WAS enrolled 93 patients (72 women, median age 38 years, BMI 47.5 kg/m2) exhibiting a relevantly compromised exercise capacity (median peakVO2 18.3 mL/min/kg) and the QoL (median physical functioning scale 50). WAS is the first randomized controlled trial focusing on the effects of RYGB on cardiovascular function beyond hypertension. In addition, it will provide a wealth of h igh-quality data on the cerebral, psychiatric, hepatic, and metabolic function in obese patients after RYGB. | ||
| 650 | 4 | |a randomized controlled trial | |
| 650 | 4 | |a morbid obesity | |
| 650 | 4 | |a roux-en-y gastric bypass | |
| 650 | 4 | |a lifestyle intervention | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a cardiovascular and brain function | |
| 650 | 4 | |a quality of life | |
| 653 | 0 | |a Diseases of the endocrine glands. Clinical endocrinology | |
| 700 | 0 | |a Bodo Warrings |e verfasserin |4 aut | |
| 700 | 0 | |a Caroline Morbach |e verfasserin |4 aut | |
| 700 | 0 | |a Florian Seyfried |e verfasserin |4 aut | |
| 700 | 0 | |a Nicole Rickert |e verfasserin |4 aut | |
| 700 | 0 | |a Pius Jung |e verfasserin |4 aut | |
| 700 | 0 | |a Andreas Geier |e verfasserin |4 aut | |
| 700 | 0 | |a Ulrich Dischinger |e verfasserin |4 aut | |
| 700 | 0 | |a Maike Krauthausen |e verfasserin |4 aut | |
| 700 | 0 | |a Martin J Herrmann |e verfasserin |4 aut | |
| 700 | 0 | |a Christine Stier |e verfasserin |4 aut | |
| 700 | 0 | |a Stefan Frantz |e verfasserin |4 aut | |
| 700 | 0 | |a Uwe Malzahn |e verfasserin |4 aut | |
| 700 | 0 | |a Stefan Störk |e verfasserin |4 aut | |
| 700 | 0 | |a Martin Fassnacht |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Endocrine Connections |d Bioscientifica, 2013 |g 11(2022), 2, Seite 17 |w (DE-627)718731077 |w (DE-600)2668428-7 |x 20493614 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:2 |g pages:17 |
| 856 | 4 | 0 | |u https://doi.org/10.1530/EC-21-0338 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/d699864de0534787aebd19b3f696e017 |z kostenfrei |
| 856 | 4 | 0 | |u https://ec.bioscientifica.com/view/journals/ec/11/2/EC-21-0338.xml |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2049-3614 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 2 |h 17 | ||
| author_variant |
a c k ack b w bw c m cm f s fs n r nr p j pj a g ag u d ud m k mk m j h mjh c s cs s f sf u m um s s ss m f mf |
|---|---|
| matchkey_str |
article:20493614:2022----::adoscoeaoiotoeobrarcugrdsgad |
| hierarchy_sort_str |
2022 |
| callnumber-subject-code |
RC |
| publishDate |
2022 |
| allfields |
(DE-627)DOAJ04593939X (DE-599)DOAJd699864de0534787aebd19b3f696e017 DE-627 ger DE-627 rakwb eng RC648-665 Ann-Cathrin Koschker verfasserin aut Cardio-psycho-metabolic outcomes of bariatric surgery: design and baseline of the WAS trial 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Obesity is a rapidly emerging health problem and an established risk factor for cardiovascular diseases. Bariatric surgery profoundly reduces body weight and mitigates sequelae of obesity. The open, randomized controlled Würzburg Adipositas Studie (WAS) trial compares the effects of Roux-en-Y gastric bypass (RYGB) vs psychotherapy-supported lifestyle modification in morbidly obese patients. The co-primar y endpoint addresses 1-year changes in cardiovascular function (peak VO2 during cardiopulmonary exercise testing) and the quality of life (QoL) (Short-Form-36 physical functioning scale). Prior to randomization, all included patients underwent a multimodal ant i-obesity treatment for 6–12 months. Thereafter, the patients were randomized and followed through month 12 to collect the primary endpoints. Afterwards, patients in the lifestyle group could opt for surgery, and final visit was scheduled for all patients 24 m onths after randomization. Sample size calculation suggested to enroll 90 patients in order to arrive at minimally 22 patients per group evaluable for the primary endpoint. Secondary objectives were to quantify changes in body weight, left ventricular hypertrophy, systolic and diastolic function (by echocardiography and cardiac MRI), functional brain MRI, psychometric scales, and endothelial and metabolic function. WAS enrolled 93 patients (72 women, median age 38 years, BMI 47.5 kg/m2) exhibiting a relevantly compromised exercise capacity (median peakVO2 18.3 mL/min/kg) and the QoL (median physical functioning scale 50). WAS is the first randomized controlled trial focusing on the effects of RYGB on cardiovascular function beyond hypertension. In addition, it will provide a wealth of h igh-quality data on the cerebral, psychiatric, hepatic, and metabolic function in obese patients after RYGB. randomized controlled trial morbid obesity roux-en-y gastric bypass lifestyle intervention heart failure cardiovascular and brain function quality of life Diseases of the endocrine glands. Clinical endocrinology Bodo Warrings verfasserin aut Caroline Morbach verfasserin aut Florian Seyfried verfasserin aut Nicole Rickert verfasserin aut Pius Jung verfasserin aut Andreas Geier verfasserin aut Ulrich Dischinger verfasserin aut Maike Krauthausen verfasserin aut Martin J Herrmann verfasserin aut Christine Stier verfasserin aut Stefan Frantz verfasserin aut Uwe Malzahn verfasserin aut Stefan Störk verfasserin aut Martin Fassnacht verfasserin aut In Endocrine Connections Bioscientifica, 2013 11(2022), 2, Seite 17 (DE-627)718731077 (DE-600)2668428-7 20493614 nnns volume:11 year:2022 number:2 pages:17 https://doi.org/10.1530/EC-21-0338 kostenfrei https://doaj.org/article/d699864de0534787aebd19b3f696e017 kostenfrei https://ec.bioscientifica.com/view/journals/ec/11/2/EC-21-0338.xml kostenfrei https://doaj.org/toc/2049-3614 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2022 2 17 |
| spelling |
(DE-627)DOAJ04593939X (DE-599)DOAJd699864de0534787aebd19b3f696e017 DE-627 ger DE-627 rakwb eng RC648-665 Ann-Cathrin Koschker verfasserin aut Cardio-psycho-metabolic outcomes of bariatric surgery: design and baseline of the WAS trial 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Obesity is a rapidly emerging health problem and an established risk factor for cardiovascular diseases. Bariatric surgery profoundly reduces body weight and mitigates sequelae of obesity. The open, randomized controlled Würzburg Adipositas Studie (WAS) trial compares the effects of Roux-en-Y gastric bypass (RYGB) vs psychotherapy-supported lifestyle modification in morbidly obese patients. The co-primar y endpoint addresses 1-year changes in cardiovascular function (peak VO2 during cardiopulmonary exercise testing) and the quality of life (QoL) (Short-Form-36 physical functioning scale). Prior to randomization, all included patients underwent a multimodal ant i-obesity treatment for 6–12 months. Thereafter, the patients were randomized and followed through month 12 to collect the primary endpoints. Afterwards, patients in the lifestyle group could opt for surgery, and final visit was scheduled for all patients 24 m onths after randomization. Sample size calculation suggested to enroll 90 patients in order to arrive at minimally 22 patients per group evaluable for the primary endpoint. Secondary objectives were to quantify changes in body weight, left ventricular hypertrophy, systolic and diastolic function (by echocardiography and cardiac MRI), functional brain MRI, psychometric scales, and endothelial and metabolic function. WAS enrolled 93 patients (72 women, median age 38 years, BMI 47.5 kg/m2) exhibiting a relevantly compromised exercise capacity (median peakVO2 18.3 mL/min/kg) and the QoL (median physical functioning scale 50). WAS is the first randomized controlled trial focusing on the effects of RYGB on cardiovascular function beyond hypertension. In addition, it will provide a wealth of h igh-quality data on the cerebral, psychiatric, hepatic, and metabolic function in obese patients after RYGB. randomized controlled trial morbid obesity roux-en-y gastric bypass lifestyle intervention heart failure cardiovascular and brain function quality of life Diseases of the endocrine glands. Clinical endocrinology Bodo Warrings verfasserin aut Caroline Morbach verfasserin aut Florian Seyfried verfasserin aut Nicole Rickert verfasserin aut Pius Jung verfasserin aut Andreas Geier verfasserin aut Ulrich Dischinger verfasserin aut Maike Krauthausen verfasserin aut Martin J Herrmann verfasserin aut Christine Stier verfasserin aut Stefan Frantz verfasserin aut Uwe Malzahn verfasserin aut Stefan Störk verfasserin aut Martin Fassnacht verfasserin aut In Endocrine Connections Bioscientifica, 2013 11(2022), 2, Seite 17 (DE-627)718731077 (DE-600)2668428-7 20493614 nnns volume:11 year:2022 number:2 pages:17 https://doi.org/10.1530/EC-21-0338 kostenfrei https://doaj.org/article/d699864de0534787aebd19b3f696e017 kostenfrei https://ec.bioscientifica.com/view/journals/ec/11/2/EC-21-0338.xml kostenfrei https://doaj.org/toc/2049-3614 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2022 2 17 |
| allfields_unstemmed |
(DE-627)DOAJ04593939X (DE-599)DOAJd699864de0534787aebd19b3f696e017 DE-627 ger DE-627 rakwb eng RC648-665 Ann-Cathrin Koschker verfasserin aut Cardio-psycho-metabolic outcomes of bariatric surgery: design and baseline of the WAS trial 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Obesity is a rapidly emerging health problem and an established risk factor for cardiovascular diseases. Bariatric surgery profoundly reduces body weight and mitigates sequelae of obesity. The open, randomized controlled Würzburg Adipositas Studie (WAS) trial compares the effects of Roux-en-Y gastric bypass (RYGB) vs psychotherapy-supported lifestyle modification in morbidly obese patients. The co-primar y endpoint addresses 1-year changes in cardiovascular function (peak VO2 during cardiopulmonary exercise testing) and the quality of life (QoL) (Short-Form-36 physical functioning scale). Prior to randomization, all included patients underwent a multimodal ant i-obesity treatment for 6–12 months. Thereafter, the patients were randomized and followed through month 12 to collect the primary endpoints. Afterwards, patients in the lifestyle group could opt for surgery, and final visit was scheduled for all patients 24 m onths after randomization. Sample size calculation suggested to enroll 90 patients in order to arrive at minimally 22 patients per group evaluable for the primary endpoint. Secondary objectives were to quantify changes in body weight, left ventricular hypertrophy, systolic and diastolic function (by echocardiography and cardiac MRI), functional brain MRI, psychometric scales, and endothelial and metabolic function. WAS enrolled 93 patients (72 women, median age 38 years, BMI 47.5 kg/m2) exhibiting a relevantly compromised exercise capacity (median peakVO2 18.3 mL/min/kg) and the QoL (median physical functioning scale 50). WAS is the first randomized controlled trial focusing on the effects of RYGB on cardiovascular function beyond hypertension. In addition, it will provide a wealth of h igh-quality data on the cerebral, psychiatric, hepatic, and metabolic function in obese patients after RYGB. randomized controlled trial morbid obesity roux-en-y gastric bypass lifestyle intervention heart failure cardiovascular and brain function quality of life Diseases of the endocrine glands. Clinical endocrinology Bodo Warrings verfasserin aut Caroline Morbach verfasserin aut Florian Seyfried verfasserin aut Nicole Rickert verfasserin aut Pius Jung verfasserin aut Andreas Geier verfasserin aut Ulrich Dischinger verfasserin aut Maike Krauthausen verfasserin aut Martin J Herrmann verfasserin aut Christine Stier verfasserin aut Stefan Frantz verfasserin aut Uwe Malzahn verfasserin aut Stefan Störk verfasserin aut Martin Fassnacht verfasserin aut In Endocrine Connections Bioscientifica, 2013 11(2022), 2, Seite 17 (DE-627)718731077 (DE-600)2668428-7 20493614 nnns volume:11 year:2022 number:2 pages:17 https://doi.org/10.1530/EC-21-0338 kostenfrei https://doaj.org/article/d699864de0534787aebd19b3f696e017 kostenfrei https://ec.bioscientifica.com/view/journals/ec/11/2/EC-21-0338.xml kostenfrei https://doaj.org/toc/2049-3614 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2022 2 17 |
| allfieldsGer |
(DE-627)DOAJ04593939X (DE-599)DOAJd699864de0534787aebd19b3f696e017 DE-627 ger DE-627 rakwb eng RC648-665 Ann-Cathrin Koschker verfasserin aut Cardio-psycho-metabolic outcomes of bariatric surgery: design and baseline of the WAS trial 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Obesity is a rapidly emerging health problem and an established risk factor for cardiovascular diseases. Bariatric surgery profoundly reduces body weight and mitigates sequelae of obesity. The open, randomized controlled Würzburg Adipositas Studie (WAS) trial compares the effects of Roux-en-Y gastric bypass (RYGB) vs psychotherapy-supported lifestyle modification in morbidly obese patients. The co-primar y endpoint addresses 1-year changes in cardiovascular function (peak VO2 during cardiopulmonary exercise testing) and the quality of life (QoL) (Short-Form-36 physical functioning scale). Prior to randomization, all included patients underwent a multimodal ant i-obesity treatment for 6–12 months. Thereafter, the patients were randomized and followed through month 12 to collect the primary endpoints. Afterwards, patients in the lifestyle group could opt for surgery, and final visit was scheduled for all patients 24 m onths after randomization. Sample size calculation suggested to enroll 90 patients in order to arrive at minimally 22 patients per group evaluable for the primary endpoint. Secondary objectives were to quantify changes in body weight, left ventricular hypertrophy, systolic and diastolic function (by echocardiography and cardiac MRI), functional brain MRI, psychometric scales, and endothelial and metabolic function. WAS enrolled 93 patients (72 women, median age 38 years, BMI 47.5 kg/m2) exhibiting a relevantly compromised exercise capacity (median peakVO2 18.3 mL/min/kg) and the QoL (median physical functioning scale 50). WAS is the first randomized controlled trial focusing on the effects of RYGB on cardiovascular function beyond hypertension. In addition, it will provide a wealth of h igh-quality data on the cerebral, psychiatric, hepatic, and metabolic function in obese patients after RYGB. randomized controlled trial morbid obesity roux-en-y gastric bypass lifestyle intervention heart failure cardiovascular and brain function quality of life Diseases of the endocrine glands. Clinical endocrinology Bodo Warrings verfasserin aut Caroline Morbach verfasserin aut Florian Seyfried verfasserin aut Nicole Rickert verfasserin aut Pius Jung verfasserin aut Andreas Geier verfasserin aut Ulrich Dischinger verfasserin aut Maike Krauthausen verfasserin aut Martin J Herrmann verfasserin aut Christine Stier verfasserin aut Stefan Frantz verfasserin aut Uwe Malzahn verfasserin aut Stefan Störk verfasserin aut Martin Fassnacht verfasserin aut In Endocrine Connections Bioscientifica, 2013 11(2022), 2, Seite 17 (DE-627)718731077 (DE-600)2668428-7 20493614 nnns volume:11 year:2022 number:2 pages:17 https://doi.org/10.1530/EC-21-0338 kostenfrei https://doaj.org/article/d699864de0534787aebd19b3f696e017 kostenfrei https://ec.bioscientifica.com/view/journals/ec/11/2/EC-21-0338.xml kostenfrei https://doaj.org/toc/2049-3614 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2022 2 17 |
| allfieldsSound |
(DE-627)DOAJ04593939X (DE-599)DOAJd699864de0534787aebd19b3f696e017 DE-627 ger DE-627 rakwb eng RC648-665 Ann-Cathrin Koschker verfasserin aut Cardio-psycho-metabolic outcomes of bariatric surgery: design and baseline of the WAS trial 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Obesity is a rapidly emerging health problem and an established risk factor for cardiovascular diseases. Bariatric surgery profoundly reduces body weight and mitigates sequelae of obesity. The open, randomized controlled Würzburg Adipositas Studie (WAS) trial compares the effects of Roux-en-Y gastric bypass (RYGB) vs psychotherapy-supported lifestyle modification in morbidly obese patients. The co-primar y endpoint addresses 1-year changes in cardiovascular function (peak VO2 during cardiopulmonary exercise testing) and the quality of life (QoL) (Short-Form-36 physical functioning scale). Prior to randomization, all included patients underwent a multimodal ant i-obesity treatment for 6–12 months. Thereafter, the patients were randomized and followed through month 12 to collect the primary endpoints. Afterwards, patients in the lifestyle group could opt for surgery, and final visit was scheduled for all patients 24 m onths after randomization. Sample size calculation suggested to enroll 90 patients in order to arrive at minimally 22 patients per group evaluable for the primary endpoint. Secondary objectives were to quantify changes in body weight, left ventricular hypertrophy, systolic and diastolic function (by echocardiography and cardiac MRI), functional brain MRI, psychometric scales, and endothelial and metabolic function. WAS enrolled 93 patients (72 women, median age 38 years, BMI 47.5 kg/m2) exhibiting a relevantly compromised exercise capacity (median peakVO2 18.3 mL/min/kg) and the QoL (median physical functioning scale 50). WAS is the first randomized controlled trial focusing on the effects of RYGB on cardiovascular function beyond hypertension. In addition, it will provide a wealth of h igh-quality data on the cerebral, psychiatric, hepatic, and metabolic function in obese patients after RYGB. randomized controlled trial morbid obesity roux-en-y gastric bypass lifestyle intervention heart failure cardiovascular and brain function quality of life Diseases of the endocrine glands. Clinical endocrinology Bodo Warrings verfasserin aut Caroline Morbach verfasserin aut Florian Seyfried verfasserin aut Nicole Rickert verfasserin aut Pius Jung verfasserin aut Andreas Geier verfasserin aut Ulrich Dischinger verfasserin aut Maike Krauthausen verfasserin aut Martin J Herrmann verfasserin aut Christine Stier verfasserin aut Stefan Frantz verfasserin aut Uwe Malzahn verfasserin aut Stefan Störk verfasserin aut Martin Fassnacht verfasserin aut In Endocrine Connections Bioscientifica, 2013 11(2022), 2, Seite 17 (DE-627)718731077 (DE-600)2668428-7 20493614 nnns volume:11 year:2022 number:2 pages:17 https://doi.org/10.1530/EC-21-0338 kostenfrei https://doaj.org/article/d699864de0534787aebd19b3f696e017 kostenfrei https://ec.bioscientifica.com/view/journals/ec/11/2/EC-21-0338.xml kostenfrei https://doaj.org/toc/2049-3614 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2022 2 17 |
| language |
English |
| source |
In Endocrine Connections 11(2022), 2, Seite 17 volume:11 year:2022 number:2 pages:17 |
| sourceStr |
In Endocrine Connections 11(2022), 2, Seite 17 volume:11 year:2022 number:2 pages:17 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
randomized controlled trial morbid obesity roux-en-y gastric bypass lifestyle intervention heart failure cardiovascular and brain function quality of life Diseases of the endocrine glands. Clinical endocrinology |
| isfreeaccess_bool |
true |
| container_title |
Endocrine Connections |
| authorswithroles_txt_mv |
Ann-Cathrin Koschker @@aut@@ Bodo Warrings @@aut@@ Caroline Morbach @@aut@@ Florian Seyfried @@aut@@ Nicole Rickert @@aut@@ Pius Jung @@aut@@ Andreas Geier @@aut@@ Ulrich Dischinger @@aut@@ Maike Krauthausen @@aut@@ Martin J Herrmann @@aut@@ Christine Stier @@aut@@ Stefan Frantz @@aut@@ Uwe Malzahn @@aut@@ Stefan Störk @@aut@@ Martin Fassnacht @@aut@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
718731077 |
| id |
DOAJ04593939X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ04593939X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308101102.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ04593939X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJd699864de0534787aebd19b3f696e017</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC648-665</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ann-Cathrin Koschker</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cardio-psycho-metabolic outcomes of bariatric surgery: design and baseline of the WAS trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Obesity is a rapidly emerging health problem and an established risk factor for cardiovascular diseases. Bariatric surgery profoundly reduces body weight and mitigates sequelae of obesity. The open, randomized controlled Würzburg Adipositas Studie (WAS) trial compares the effects of Roux-en-Y gastric bypass (RYGB) vs psychotherapy-supported lifestyle modification in morbidly obese patients. The co-primar y endpoint addresses 1-year changes in cardiovascular function (peak VO2 during cardiopulmonary exercise testing) and the quality of life (QoL) (Short-Form-36 physical functioning scale). Prior to randomization, all included patients underwent a multimodal ant i-obesity treatment for 6–12 months. Thereafter, the patients were randomized and followed through month 12 to collect the primary endpoints. Afterwards, patients in the lifestyle group could opt for surgery, and final visit was scheduled for all patients 24 m onths after randomization. Sample size calculation suggested to enroll 90 patients in order to arrive at minimally 22 patients per group evaluable for the primary endpoint. Secondary objectives were to quantify changes in body weight, left ventricular hypertrophy, systolic and diastolic function (by echocardiography and cardiac MRI), functional brain MRI, psychometric scales, and endothelial and metabolic function. WAS enrolled 93 patients (72 women, median age 38 years, BMI 47.5 kg/m2) exhibiting a relevantly compromised exercise capacity (median peakVO2 18.3 mL/min/kg) and the QoL (median physical functioning scale 50). WAS is the first randomized controlled trial focusing on the effects of RYGB on cardiovascular function beyond hypertension. In addition, it will provide a wealth of h igh-quality data on the cerebral, psychiatric, hepatic, and metabolic function in obese patients after RYGB.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">randomized controlled trial</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">morbid obesity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">roux-en-y gastric bypass</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lifestyle intervention</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">heart failure</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cardiovascular and brain function</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">quality of life</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the endocrine glands. Clinical endocrinology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bodo Warrings</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Caroline Morbach</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Florian Seyfried</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicole Rickert</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pius Jung</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andreas Geier</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ulrich Dischinger</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maike Krauthausen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Martin J Herrmann</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Christine Stier</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefan Frantz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Uwe Malzahn</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefan Störk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Martin Fassnacht</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Endocrine Connections</subfield><subfield code="d">Bioscientifica, 2013</subfield><subfield code="g">11(2022), 2, Seite 17</subfield><subfield code="w">(DE-627)718731077</subfield><subfield code="w">(DE-600)2668428-7</subfield><subfield code="x">20493614</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:17</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1530/EC-21-0338</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/d699864de0534787aebd19b3f696e017</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ec.bioscientifica.com/view/journals/ec/11/2/EC-21-0338.xml</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2049-3614</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2022</subfield><subfield code="e">2</subfield><subfield code="h">17</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Ann-Cathrin Koschker |
| spellingShingle |
Ann-Cathrin Koschker misc RC648-665 misc randomized controlled trial misc morbid obesity misc roux-en-y gastric bypass misc lifestyle intervention misc heart failure misc cardiovascular and brain function misc quality of life misc Diseases of the endocrine glands. Clinical endocrinology Cardio-psycho-metabolic outcomes of bariatric surgery: design and baseline of the WAS trial |
| authorStr |
Ann-Cathrin Koschker |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)718731077 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RC648-665 |
| illustrated |
Not Illustrated |
| issn |
20493614 |
| topic_title |
RC648-665 Cardio-psycho-metabolic outcomes of bariatric surgery: design and baseline of the WAS trial randomized controlled trial morbid obesity roux-en-y gastric bypass lifestyle intervention heart failure cardiovascular and brain function quality of life |
| topic |
misc RC648-665 misc randomized controlled trial misc morbid obesity misc roux-en-y gastric bypass misc lifestyle intervention misc heart failure misc cardiovascular and brain function misc quality of life misc Diseases of the endocrine glands. Clinical endocrinology |
| topic_unstemmed |
misc RC648-665 misc randomized controlled trial misc morbid obesity misc roux-en-y gastric bypass misc lifestyle intervention misc heart failure misc cardiovascular and brain function misc quality of life misc Diseases of the endocrine glands. Clinical endocrinology |
| topic_browse |
misc RC648-665 misc randomized controlled trial misc morbid obesity misc roux-en-y gastric bypass misc lifestyle intervention misc heart failure misc cardiovascular and brain function misc quality of life misc Diseases of the endocrine glands. Clinical endocrinology |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Endocrine Connections |
| hierarchy_parent_id |
718731077 |
| hierarchy_top_title |
Endocrine Connections |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)718731077 (DE-600)2668428-7 |
| title |
Cardio-psycho-metabolic outcomes of bariatric surgery: design and baseline of the WAS trial |
| ctrlnum |
(DE-627)DOAJ04593939X (DE-599)DOAJd699864de0534787aebd19b3f696e017 |
| title_full |
Cardio-psycho-metabolic outcomes of bariatric surgery: design and baseline of the WAS trial |
| author_sort |
Ann-Cathrin Koschker |
| journal |
Endocrine Connections |
| journalStr |
Endocrine Connections |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
txt |
| container_start_page |
17 |
| author_browse |
Ann-Cathrin Koschker Bodo Warrings Caroline Morbach Florian Seyfried Nicole Rickert Pius Jung Andreas Geier Ulrich Dischinger Maike Krauthausen Martin J Herrmann Christine Stier Stefan Frantz Uwe Malzahn Stefan Störk Martin Fassnacht |
| container_volume |
11 |
| class |
RC648-665 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Ann-Cathrin Koschker |
| author2-role |
verfasserin |
| title_sort |
cardio-psycho-metabolic outcomes of bariatric surgery: design and baseline of the was trial |
| callnumber |
RC648-665 |
| title_auth |
Cardio-psycho-metabolic outcomes of bariatric surgery: design and baseline of the WAS trial |
| abstract |
Obesity is a rapidly emerging health problem and an established risk factor for cardiovascular diseases. Bariatric surgery profoundly reduces body weight and mitigates sequelae of obesity. The open, randomized controlled Würzburg Adipositas Studie (WAS) trial compares the effects of Roux-en-Y gastric bypass (RYGB) vs psychotherapy-supported lifestyle modification in morbidly obese patients. The co-primar y endpoint addresses 1-year changes in cardiovascular function (peak VO2 during cardiopulmonary exercise testing) and the quality of life (QoL) (Short-Form-36 physical functioning scale). Prior to randomization, all included patients underwent a multimodal ant i-obesity treatment for 6–12 months. Thereafter, the patients were randomized and followed through month 12 to collect the primary endpoints. Afterwards, patients in the lifestyle group could opt for surgery, and final visit was scheduled for all patients 24 m onths after randomization. Sample size calculation suggested to enroll 90 patients in order to arrive at minimally 22 patients per group evaluable for the primary endpoint. Secondary objectives were to quantify changes in body weight, left ventricular hypertrophy, systolic and diastolic function (by echocardiography and cardiac MRI), functional brain MRI, psychometric scales, and endothelial and metabolic function. WAS enrolled 93 patients (72 women, median age 38 years, BMI 47.5 kg/m2) exhibiting a relevantly compromised exercise capacity (median peakVO2 18.3 mL/min/kg) and the QoL (median physical functioning scale 50). WAS is the first randomized controlled trial focusing on the effects of RYGB on cardiovascular function beyond hypertension. In addition, it will provide a wealth of h igh-quality data on the cerebral, psychiatric, hepatic, and metabolic function in obese patients after RYGB. |
| abstractGer |
Obesity is a rapidly emerging health problem and an established risk factor for cardiovascular diseases. Bariatric surgery profoundly reduces body weight and mitigates sequelae of obesity. The open, randomized controlled Würzburg Adipositas Studie (WAS) trial compares the effects of Roux-en-Y gastric bypass (RYGB) vs psychotherapy-supported lifestyle modification in morbidly obese patients. The co-primar y endpoint addresses 1-year changes in cardiovascular function (peak VO2 during cardiopulmonary exercise testing) and the quality of life (QoL) (Short-Form-36 physical functioning scale). Prior to randomization, all included patients underwent a multimodal ant i-obesity treatment for 6–12 months. Thereafter, the patients were randomized and followed through month 12 to collect the primary endpoints. Afterwards, patients in the lifestyle group could opt for surgery, and final visit was scheduled for all patients 24 m onths after randomization. Sample size calculation suggested to enroll 90 patients in order to arrive at minimally 22 patients per group evaluable for the primary endpoint. Secondary objectives were to quantify changes in body weight, left ventricular hypertrophy, systolic and diastolic function (by echocardiography and cardiac MRI), functional brain MRI, psychometric scales, and endothelial and metabolic function. WAS enrolled 93 patients (72 women, median age 38 years, BMI 47.5 kg/m2) exhibiting a relevantly compromised exercise capacity (median peakVO2 18.3 mL/min/kg) and the QoL (median physical functioning scale 50). WAS is the first randomized controlled trial focusing on the effects of RYGB on cardiovascular function beyond hypertension. In addition, it will provide a wealth of h igh-quality data on the cerebral, psychiatric, hepatic, and metabolic function in obese patients after RYGB. |
| abstract_unstemmed |
Obesity is a rapidly emerging health problem and an established risk factor for cardiovascular diseases. Bariatric surgery profoundly reduces body weight and mitigates sequelae of obesity. The open, randomized controlled Würzburg Adipositas Studie (WAS) trial compares the effects of Roux-en-Y gastric bypass (RYGB) vs psychotherapy-supported lifestyle modification in morbidly obese patients. The co-primar y endpoint addresses 1-year changes in cardiovascular function (peak VO2 during cardiopulmonary exercise testing) and the quality of life (QoL) (Short-Form-36 physical functioning scale). Prior to randomization, all included patients underwent a multimodal ant i-obesity treatment for 6–12 months. Thereafter, the patients were randomized and followed through month 12 to collect the primary endpoints. Afterwards, patients in the lifestyle group could opt for surgery, and final visit was scheduled for all patients 24 m onths after randomization. Sample size calculation suggested to enroll 90 patients in order to arrive at minimally 22 patients per group evaluable for the primary endpoint. Secondary objectives were to quantify changes in body weight, left ventricular hypertrophy, systolic and diastolic function (by echocardiography and cardiac MRI), functional brain MRI, psychometric scales, and endothelial and metabolic function. WAS enrolled 93 patients (72 women, median age 38 years, BMI 47.5 kg/m2) exhibiting a relevantly compromised exercise capacity (median peakVO2 18.3 mL/min/kg) and the QoL (median physical functioning scale 50). WAS is the first randomized controlled trial focusing on the effects of RYGB on cardiovascular function beyond hypertension. In addition, it will provide a wealth of h igh-quality data on the cerebral, psychiatric, hepatic, and metabolic function in obese patients after RYGB. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
| container_issue |
2 |
| title_short |
Cardio-psycho-metabolic outcomes of bariatric surgery: design and baseline of the WAS trial |
| url |
https://doi.org/10.1530/EC-21-0338 https://doaj.org/article/d699864de0534787aebd19b3f696e017 https://ec.bioscientifica.com/view/journals/ec/11/2/EC-21-0338.xml https://doaj.org/toc/2049-3614 |
| remote_bool |
true |
| author2 |
Bodo Warrings Caroline Morbach Florian Seyfried Nicole Rickert Pius Jung Andreas Geier Ulrich Dischinger Maike Krauthausen Martin J Herrmann Christine Stier Stefan Frantz Uwe Malzahn Stefan Störk Martin Fassnacht |
| author2Str |
Bodo Warrings Caroline Morbach Florian Seyfried Nicole Rickert Pius Jung Andreas Geier Ulrich Dischinger Maike Krauthausen Martin J Herrmann Christine Stier Stefan Frantz Uwe Malzahn Stefan Störk Martin Fassnacht |
| ppnlink |
718731077 |
| callnumber-subject |
RC - Internal Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| callnumber-a |
RC648-665 |
| up_date |
2024-07-03T17:54:25.391Z |
| _version_ |
1803581406986633216 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ04593939X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308101102.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ04593939X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJd699864de0534787aebd19b3f696e017</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC648-665</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ann-Cathrin Koschker</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cardio-psycho-metabolic outcomes of bariatric surgery: design and baseline of the WAS trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Obesity is a rapidly emerging health problem and an established risk factor for cardiovascular diseases. Bariatric surgery profoundly reduces body weight and mitigates sequelae of obesity. The open, randomized controlled Würzburg Adipositas Studie (WAS) trial compares the effects of Roux-en-Y gastric bypass (RYGB) vs psychotherapy-supported lifestyle modification in morbidly obese patients. The co-primar y endpoint addresses 1-year changes in cardiovascular function (peak VO2 during cardiopulmonary exercise testing) and the quality of life (QoL) (Short-Form-36 physical functioning scale). Prior to randomization, all included patients underwent a multimodal ant i-obesity treatment for 6–12 months. Thereafter, the patients were randomized and followed through month 12 to collect the primary endpoints. Afterwards, patients in the lifestyle group could opt for surgery, and final visit was scheduled for all patients 24 m onths after randomization. Sample size calculation suggested to enroll 90 patients in order to arrive at minimally 22 patients per group evaluable for the primary endpoint. Secondary objectives were to quantify changes in body weight, left ventricular hypertrophy, systolic and diastolic function (by echocardiography and cardiac MRI), functional brain MRI, psychometric scales, and endothelial and metabolic function. WAS enrolled 93 patients (72 women, median age 38 years, BMI 47.5 kg/m2) exhibiting a relevantly compromised exercise capacity (median peakVO2 18.3 mL/min/kg) and the QoL (median physical functioning scale 50). WAS is the first randomized controlled trial focusing on the effects of RYGB on cardiovascular function beyond hypertension. In addition, it will provide a wealth of h igh-quality data on the cerebral, psychiatric, hepatic, and metabolic function in obese patients after RYGB.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">randomized controlled trial</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">morbid obesity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">roux-en-y gastric bypass</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lifestyle intervention</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">heart failure</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cardiovascular and brain function</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">quality of life</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the endocrine glands. Clinical endocrinology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bodo Warrings</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Caroline Morbach</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Florian Seyfried</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicole Rickert</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pius Jung</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andreas Geier</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ulrich Dischinger</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maike Krauthausen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Martin J Herrmann</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Christine Stier</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefan Frantz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Uwe Malzahn</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefan Störk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Martin Fassnacht</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Endocrine Connections</subfield><subfield code="d">Bioscientifica, 2013</subfield><subfield code="g">11(2022), 2, Seite 17</subfield><subfield code="w">(DE-627)718731077</subfield><subfield code="w">(DE-600)2668428-7</subfield><subfield code="x">20493614</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:17</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1530/EC-21-0338</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/d699864de0534787aebd19b3f696e017</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ec.bioscientifica.com/view/journals/ec/11/2/EC-21-0338.xml</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2049-3614</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2022</subfield><subfield code="e">2</subfield><subfield code="h">17</subfield></datafield></record></collection>
|
| score |
7.4008837 |